THE HEALTH AND ECONOMIC CONSEQUENCES OF DELAY IN STARTING DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS) IN RHEUMATOID ARTHRITIS

被引：0
|
作者：
Van Doornum, S. [1 ,2 ]
Franklyn, K. [2 ]
Tacey, M. [1 ,2 ]
Roberts, C. [1 ,2 ]
Liew, D. [1 ,2 ]
机构：
[1] Univ Melbourne, Melbourne, Vic 3010, Australia
[2] Royal Melbourne Hosp, Melbourne, Vic, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2013年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2 / 2
页数：1
相关论文
共 50 条
  • [31] Factors associated with discontinuation of glucocorticoids after starting biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients
    Inoue, Mariko
    Kanda, Hiroko
    Tateishi, Shoko
    Fujio, Keishi
    [J]. MODERN RHEUMATOLOGY, 2020, 30 (01) : 58 - 63
  • [32] Pneumonia vaccination timing in relation to starting conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis
    Costello, Ruth E.
    Humphreys, Jenny H.
    Winthrop, Kevin L.
    Dixon, William G.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (12) : 1665 - 1666
  • [33] Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis
    van Riel, PLCM
    Haagsma, CJ
    Furst, DE
    [J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 1999, 13 (04): : 689 - 700
  • [34] The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
    Ozen, Gulsen
    Pedro, Sofia
    Michaud, Kaleb
    [J]. JOURNAL OF RHEUMATOLOGY, 2021, 48 (05) : 648 - 655
  • [35] DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARD) IN THE TREATMENT OF PATIENTS WITH RHEUMATOID-ARTHRITIS
    HALBERG, P
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1986, : 55 - 57
  • [36] SAFETY OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN JUVENILE RHEUMATOID-ARTHRITIS (JRA)
    KVIEN, TK
    HOYERAAL, HM
    SANDSTAD, B
    KASS, E
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 1984, : 112 - 112
  • [37] Is the outcome of rheumatoid arthritis changed with the use of new disease-modifying antirheumatic drugs?
    Kremer, J
    [J]. ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2005, 53 (05): : 636 - 638
  • [38] The Efficacy of Biological Disease-modifying Antirheumatic Drugs on Sarcopenia in Patients with Rheumatoid Arthritis
    Hasegawa, Eriko
    Ito, Satoshi
    Kurosawa, Yoichi
    Kobayashi, Daisuke
    Otani, Hiroshi
    Abe, Asami
    Nakazono, Kiyoshi
    Murasawa, Akira
    Narita, Ichiei
    Ishikawa, Hajime
    [J]. INTERNAL MEDICINE, 2023, 62 (03) : 373 - 379
  • [39] Pharmacoepidemiological analysis of disease-modifying antirheumatic drugs adverse effects in rheumatoid arthritis
    Reshetko, O.
    Levitan, A.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 : S33 - S33
  • [40] Disease-modifying antirheumatic drugs in rheumatoid arthritis patients with a history of colorectal cancer
    Kleinert, S.
    Waldner, M.
    Wendler, J.
    Kunzmann, V.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2016, 75 (01): : 41 - 46
12345